Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
Genesis Molecular AI
Generative and predictive AI platform (GEMS) for small-molecule drug discovery, from hit identification through lead optimization.
Genesis Molecular AI (formerly Genesis Therapeutics), founded in 2019 out of Vijay Pande's lab at Stanford University, develops GEMS (Genesis Exploration of Molecular Space), a generative and predictive AI platform for small-molecule drug discovery. The platform combines deep learning for molecular property prediction with drug–protein structure modeling to design and optimize novel compounds, and the company runs AI-focused research collaborations with pharmaceutical partners.
- Headquarters
- Burlingame, United States
- Founded
- 2019
- Deployment options
- cloud
- Website
- https://www.genesis.ml
- https://www.linkedin.com/company/genesis-molecular-ai
Categories
AI Use Cases
- ADMET & Toxicity Prediction
- Hit Identification & Lead Optimization
Vendor Scorecard
86% — Complete coverage. Coverage score — how completely Atlas documents Genesis Molecular AI across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Documented
Partnership / milestone based
Implementation & Onboarding — Documented
12+ months
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Drug Discovery, R&D Leadership
Solution Scope — Documented
ADMET Prediction, Molecular Generation, Protein Structure Prediction
Company Viability — Documented
Series B, $304M raised, 150+ employees, Founded 2019
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Evidence & Outcomes
Eli Lilly collaboration worth up to $670 million to discover novel therapies
Genesis Therapeutics (now Genesis Molecular AI) entered a strategic collaboration with Eli Lilly to discover novel therapies for up to five targets across a range of therapeutic areas using its Genesis Molecular AI drug-discovery platform, receiving $20 million upfront with a potential total value of up to $670 million.
press release (Genesis Therapeutics (Business Wire)) · 2022-05-03 — Partner: Eli Lilly and Company
Questions to Ask This Vendor
- How is GEMS-predicted binding affinity validated against wet-lab results?
- Which therapeutic areas have the deepest training data?
- How is IP for AI-generated molecules structured in partnerships?
- What does a typical research collaboration scope and timeline look like?